Article Information
History
- December 2, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Madison Stoddard1,
- Debra Van Egeren2,3,4,
- Kaitlyn Johnson5,
- Smriti Rao6,
- Josh Furgeson7,
- Douglas E. White8,
- Ryan P. Nolan9,
- Natasha Hochberg10,11,12 and
- Arijit Chakravarty1,*
- 1Fractal Therapeutics, Cambridge, MA, USA
- 2Harvard Medical School, Boston, MA, USA
- 3Dana-Farber Cancer Institute, Boston, MA, USA
- 4Boston Children’s Hospital, Boston, MA, USA
- 5Department of Biomedical Engineering, University of Texas, Austin, TX, USA
- 6Department of Economics, Assumption College, Worcester, MA, USA
- 7International Initiative for Impact Evaluation, Cambridge, MA, USA
- 8Independent Researcher
- 9Halozyme Therapeutics, San Diego, CA, USA
- 10Boston Medical Center, Boston, MA, USA
- 11Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
- 12Department of Medicine, Boston University School of Medicine, Boston, MA, USA
- ↵*Corresponding author, email: arijit{at}fractaltx.com